EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
Status:
Completed
Trial end date:
2017-12-30
Target enrollment:
Participant gender:
Summary
To compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential
treatment after patients gradually progressed from first-line EGFR-TKI treatment.
Patients who had gradual progression and EGFR-T790M mutation-negative were randomly divided
into two groups: in concurrent group, patients were treated with pemetrexed plus cisplatin
along with the same EGFR-TKI; in sequential group, patients continued with EGFR-TKI until the
disease progressed again according to the RECIST criteria, and then switched to chemotherapy.
We evaluated progression-free survival (PFS) and overall survival (OS) time of patients. For
sequential group, PFS was PFS1 (gradual progression to discontinue EGFR-TKI) plus PFS2
(chemotherapy alone).